IN2014MU00303A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU00303A IN2014MU00303A IN303MU2014A IN2014MU00303A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A IN 303MU2014 A IN303MU2014 A IN 303MU2014A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical composition
- relates
- abiraterone
- abstract
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/050175 WO2015114314A1 (en) | 2014-01-28 | 2015-01-27 | Pharmaceutical composition comprising abiraterone |
| IN303MU2014 IN2014MU00303A (ar) | 2014-01-28 | 2015-01-27 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN303MU2014 IN2014MU00303A (ar) | 2014-01-28 | 2015-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU00303A true IN2014MU00303A (ar) | 2015-09-11 |
Family
ID=52462940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN303MU2014 IN2014MU00303A (ar) | 2014-01-28 | 2015-01-27 |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2014MU00303A (ar) |
| WO (1) | WO2015114314A1 (ar) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| CA3036011A1 (en) * | 2016-08-20 | 2018-03-01 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| DK3660004T3 (da) | 2016-10-11 | 2023-05-08 | Arvinas Operations Inc | Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor |
| EP3784218A1 (en) | 2018-04-26 | 2021-03-03 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| SG11202107948PA (en) * | 2018-12-20 | 2021-08-30 | Pharmaceutical Oriented Services Ltd | Dosage form containing abiraterone acetate |
| US20220257613A1 (en) * | 2019-07-15 | 2022-08-18 | Shilpa Medicare Ltd | Dispersible tablets of abiraterone acetate |
| WO2021081108A1 (en) * | 2019-10-22 | 2021-04-29 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
| CN113384532B (zh) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | 一种cyp17抑制剂固体分散体及其制备方法 |
| EP3944860A1 (en) * | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
| CN115475172B (zh) * | 2021-06-15 | 2023-12-01 | 北京泰德制药股份有限公司 | 一种含有阿比特龙或其药用盐的药用组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140166A1 (es) * | 2010-10-01 | 2014-02-17 | Cipla Ltd | Composicion farmaceutica que comprende deferasirox |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
-
2015
- 2015-01-27 WO PCT/GB2015/050175 patent/WO2015114314A1/en active Application Filing
- 2015-01-27 IN IN303MU2014 patent/IN2014MU00303A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015114314A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008686A (es) | Polinucleotidos moduladores. | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| PT3616720T (pt) | Composição medicinal para tratamento de cancro | |
| IN2014MU00303A (ar) | ||
| TW201613901A (en) | New compounds | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MX2018003563A (es) | Nuevos compuestos. | |
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| MX2017009608A (es) | Compuestos anticancerigenos. | |
| IN2014MU00495A (ar) | ||
| GB201719584D0 (en) | Pharmaceutical compositions for the treatment of cancer | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer |